Top Qs
Timeline
Chat
Perspective
DOB-NBOMe
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
DOB-NBOMe, or NBOMe-DOB, also known as N-(2-methoxybenzyl)-4-bromo-2,5-dimethoxyamphetamine, is a serotonin 5-HT2A receptor agonist and possible psychedelic drug of the phenethylamine, DOx, and 25-NB (NBOMe) families.[1][2][3] It is the N-(2-methoxybenzyl) derivative of DOB and the amphetamine (i.e., α-methyl) analogue of 25B-NBOMe.[1][2][3]
Remove ads
Pharmacology
Summarize
Perspective
The drug is a potent serotonin 5-HT2A receptor partial agonist, with an EC50 of 7.94 nM and an Emax of 20% in the employed assay.[1][2][3] As an agonist of the serotonin 5-HT2A receptor, DOB-NBOMe had about the same potency as DOB but had greatly reduced efficacy in comparison in vitro (with DOB having an EC50 of 10.2 nM and an Emax of 71%).[1][2][3] Compared to 25B-NBOMe, the corresponding NBOMe analogue of 2C-B, DOB-NBOMe had about 30-fold lower potency as a serotonin 5-HT2A receptor agonist and about half the activational efficacy.[1][2][3] Whereas the potency of 2Cs can be dramatically increased by N-(2-methoxybenzyl) substitution, this has not been the case with the DOx series of psychedelics, where activity has been negatively impacted.[4][5][6][1][2][3]
Remove ads
History
DOB-NBOMe was first described in the scientific literature by Ralf Heim by 2003.[1]
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads